CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...
Phase 3
Montréal, Quebec, Canada and 143 other locations
of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic...
Phase 3
Greenfield Park, Quebec, Canada and 47 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Montreal, Quebec, Canada and 86 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Montreal, Quebec, Canada and 216 other locations
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...
Phase 1, Phase 2
Montréal, Quebec, Canada and 48 other locations
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...
Phase 3
Montreal, Quebec, Canada and 170 other locations
venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medic...
Phase 3
Montreal, Quebec, Canada and 136 other locations
the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic...
Phase 3
Montreal, Canada and 156 other locations
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...
Phase 1
Montreal, Quebec, Canada and 23 other locations
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...
Phase 3
Montreal, Quebec, Canada and 173 other locations
Clinical trials
Research sites
Resources
Legal